Aptevo Therapeutics Files 8-K with Key Updates
Ticker: APVO · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-reporting, corporate-update
Related Tickers: APVO
TL;DR
APVO filed an 8-K on 4/28/25 covering material agreements and financials.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on April 28, 2025, reporting on several key events. These include entering into a material definitive agreement, updates on results of operations and financial condition, and other events. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on Aptevo Therapeutics' material agreements and financial performance, which are important for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate events and financial reporting, which can introduce volatility and require careful investor scrutiny.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- April 28, 2025 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What specific material definitive agreement did Aptevo Therapeutics enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What are the key updates regarding Aptevo Therapeutics' results of operations and financial condition?
The 8-K filing notes that there are updates on results of operations and financial condition, but the specific details are not elaborated in the provided text.
What other events are reported in this 8-K filing?
The filing states 'Other Events' as an item of information, but the nature of these events is not specified in the provided text.
When was this 8-K report filed?
This 8-K report was filed on April 28, 2025.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Aptevo Therapeutics Inc. (APVO).